Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The impact of mpMRI-targeted vs systematic biopsy on the risk of prostate cancer downgrading at final pathology.
Sorce G, Stabile A, Pellegrino F, Mazzone E, Mattei A, Afferi L, Serni S, Minervini A, Roumiguiè M, Malavaud B, Valerio M, Rakauskas A, Marra G, Gontero P, Porpiglia F, Guo H, Zhuang J, Gandaglia G, Montorsi F, Briganti A. Sorce G, et al. World J Urol. 2024 Apr 22;42(1):248. doi: 10.1007/s00345-024-04963-w. World J Urol. 2024. PMID: 38647689
Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.
Mazzone E, Stabile A, Pellegrino F, Basile G, Cignoli D, Cirulli GO, Sorce G, Barletta F, Scuderi S, Bravi CA, Cucchiara V, Fossati N, Gandaglia G, Montorsi F, Briganti A. Mazzone E, et al. Among authors: sorce g. Eur Urol Oncol. 2021 Oct;4(5):697-713. doi: 10.1016/j.euo.2020.12.004. Epub 2020 Dec 25. Eur Urol Oncol. 2021. PMID: 33358543 Review.
Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era?
Mazzone E, Stabile A, Sorce G, Pellegrino F, Barletta F, Motterle G, Scuderi S, Cirulli GO, Cucchiara V, Brembilla G, Esposito A, Gandaglia G, Fossati N, De Cobelli F, Montorsi F, Karnes RJ, Guccini I, Briganti A. Mazzone E, et al. Among authors: sorce g. Urol Oncol. 2021 Nov;39(11):784.e1-784.e9. doi: 10.1016/j.urolonc.2021.03.013. Epub 2021 Apr 15. Urol Oncol. 2021. PMID: 33865687
Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series.
Stabile A, Barletta F, Motterle G, Pellegrino F, Sorce G, Mazzone E, Scuderi S, Cirulli GO, Cucchiara V, Esposito A, Gandaglia G, Fossati N, De Cobelli F, Montorsi F, Karnes RJ, Briganti A. Stabile A, et al. Among authors: sorce g. Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1137-1142. doi: 10.1038/s41391-021-00371-y. Epub 2021 May 3. Prostate Cancer Prostatic Dis. 2021. PMID: 33941867
Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients.
Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, Shariat SF, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Hoeh B, et al. Among authors: sorce g. Prostate. 2022 Jan;82(1):120-131. doi: 10.1002/pros.24253. Epub 2021 Oct 18. Prostate. 2022. PMID: 34662443
How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series.
Barletta F, Stabile A, Mazzone E, Brembilla G, Sorce G, Pellegrino F, Scuderi S, Cannoletta D, Cirulli GO, Cucchiara V, Gandaglia G, De Cobelli F, Montorsi F, Briganti A. Barletta F, et al. Among authors: sorce g. Urol Oncol. 2022 Mar;40(3):103.e17-103.e24. doi: 10.1016/j.urolonc.2021.09.015. Epub 2021 Oct 27. Urol Oncol. 2022. PMID: 34688534
Cancer-specific mortality after radical prostatectomy vs external beam radiotherapy in high-risk Hispanic/Latino prostate cancer patients.
Hoeh B, Hohenhorst JL, Flammia R, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, Shariat SF, Kluth LA, Becker A, Chun FKH, Karakiewicz PI. Hoeh B, et al. Among authors: sorce g. Int Urol Nephrol. 2022 Jan;54(1):81-87. doi: 10.1007/s11255-021-03055-7. Epub 2021 Nov 16. Int Urol Nephrol. 2022. PMID: 34783982 Free PMC article.
Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review.
Ratti MM, Gandaglia G, Alleva E, Leardini L, Sisca ES, Derevianko A, Furnari F, Mazzoleni Ferracini S, Beyer K, Moss C, Pellegrino F, Sorce G, Barletta F, Scuderi S, Omar MI, MacLennan S, Williamson PR, Zong J, MacLennan SJ, Mottet N, Cornford P, Aiyegbusi OL, Van Hemelrijck M, N'Dow J, Briganti A; PIONEER Consortium. Ratti MM, et al. Among authors: sorce g. Eur Urol Oncol. 2022 Apr;5(2):153-163. doi: 10.1016/j.euo.2021.10.004. Epub 2021 Nov 14. Eur Urol Oncol. 2022. PMID: 34785188 Free article.
Survival after radical prostatectomy vs. radiation therapy in ductal carcinoma of the prostate.
Chierigo F, Borghesi M, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Höh B, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Montorsi F, Chun FKH, Shariat SF, Mantica G, Suardi N, Terrone C, Karakiewicz PI. Chierigo F, et al. Among authors: sorce g. Int Urol Nephrol. 2022 Jan;54(1):89-95. doi: 10.1007/s11255-021-03070-8. Epub 2021 Nov 19. Int Urol Nephrol. 2022. PMID: 34797483
81 results